SG152025A1 - Pharmaceutical combinations and their use in treating gastrointestinal disorders - Google Patents

Pharmaceutical combinations and their use in treating gastrointestinal disorders

Info

Publication number
SG152025A1
SG152025A1 SG200404415-2A SG2004044152A SG152025A1 SG 152025 A1 SG152025 A1 SG 152025A1 SG 2004044152 A SG2004044152 A SG 2004044152A SG 152025 A1 SG152025 A1 SG 152025A1
Authority
SG
Singapore
Prior art keywords
gastrointestinal disorders
pharmaceutical combinations
treating gastrointestinal
combination
agent
Prior art date
Application number
SG200404415-2A
Other languages
English (en)
Inventor
Stephan Anthony Billstein
Peter Dumovic
Nicola Franco
Mark Thomas Iwicki
Hans-Jurgen Pfannkuche
Edward Joseph Wilusz Jr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG152025A1 publication Critical patent/SG152025A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200404415-2A 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders SG152025A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
SG152025A1 true SG152025A1 (en) 2009-05-29

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200404415-2A SG152025A1 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Country Status (30)

Country Link
EP (3) EP1286668B1 (es)
JP (1) JP2003523324A (es)
KR (1) KR100765579B1 (es)
CN (2) CN1310644C (es)
AR (1) AR026916A1 (es)
AT (1) ATE293971T1 (es)
AU (2) AU778869B2 (es)
BR (1) BR0016275A (es)
CA (1) CA2388959A1 (es)
CO (1) CO5261535A1 (es)
CZ (1) CZ300690B6 (es)
DE (1) DE60019814T2 (es)
DK (1) DK1286668T3 (es)
ES (1) ES2240229T3 (es)
HU (1) HUP0301122A3 (es)
IL (2) IL149496A0 (es)
MX (1) MXPA02005695A (es)
MY (1) MY133423A (es)
NO (1) NO20022680L (es)
NZ (2) NZ531489A (es)
PE (1) PE20011030A1 (es)
PL (1) PL202201B1 (es)
PT (1) PT1286668E (es)
RU (1) RU2264215C2 (es)
SG (1) SG152025A1 (es)
SK (1) SK8062002A3 (es)
TR (1) TR200402293T2 (es)
TW (1) TWI263496B (es)
WO (1) WO2001041748A2 (es)
ZA (1) ZA200204493B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
DE602004005814T2 (de) 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
US20060241134A1 (en) * 2003-05-27 2006-10-26 Altana Pharma Ga Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
RU2007105346A (ru) * 2004-07-14 2008-09-27 Новартис АГ (CH) Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы
JP2008528615A (ja) * 2005-01-31 2008-07-31 ノバルティス アクチエンゲゼルシャフト プロトンポンプ阻害剤により誘発され得る遅延した胃内容排出の処置のための５−ｈｔ４アゴニストの使用
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
MX2008015967A (es) * 2006-06-15 2009-01-09 Novartis Ag Composiciones que comprenden tegaserod solo o en combinacion con un inhibidor de la bomba de protones, para el tratamiento o la prevencion de lesion gastrica.
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
JP2011503073A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． コルチコステロイド組成物
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR20230044038A (ko) 2016-08-09 2023-03-31 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505322A1 (en) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
WO1994001095A2 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Medicaments for the treatment of visceral pain and migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0617620T3 (da) * 1991-12-21 1999-06-07 Smithkline Beecham Plc Anvendelse af 5-HT4-modulatorer til fremstilling af et lægemiddel til behandling af blærelidelser
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505322A1 (en) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
WO1994001095A2 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Medicaments for the treatment of visceral pain and migraine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TEGASEROD SELECTIVE 5- HYDROXYTRYPTAMINE TYPE 3 RECEPTOR ANTAGONISM WITH ONDANSETRON AS TREATMENT FOR DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: A PILOT STU *

Also Published As

Publication number Publication date
ZA200204493B (en) 2003-09-29
CA2388959A1 (en) 2001-06-14
EP1913944A1 (en) 2008-04-23
CN1409634A (zh) 2003-04-09
KR100765579B1 (ko) 2007-10-09
DE60019814D1 (de) 2005-06-02
CZ300690B6 (cs) 2009-07-15
NZ566800A (en) 2009-11-27
RU2002118316A (ru) 2004-02-20
HUP0301122A2 (hu) 2003-08-28
RU2264215C2 (ru) 2005-11-20
PE20011030A1 (es) 2001-10-31
JP2003523324A (ja) 2003-08-05
WO2001041748A3 (en) 2002-12-19
DE60019814T2 (de) 2006-03-02
BR0016275A (pt) 2002-08-27
NO20022680D0 (no) 2002-06-06
KR20030016208A (ko) 2003-02-26
ES2240229T3 (es) 2005-10-16
SK8062002A3 (en) 2003-04-01
MY133423A (en) 2007-11-30
CO5261535A1 (es) 2003-03-31
CZ20021967A3 (cs) 2002-08-14
AU2005200797B2 (en) 2008-01-24
ATE293971T1 (de) 2005-05-15
IL149496A0 (en) 2002-11-10
EP1286668A2 (en) 2003-03-05
PL355663A1 (en) 2004-05-04
EP1488788A1 (en) 2004-12-22
WO2001041748A2 (en) 2001-06-14
CN1310644C (zh) 2007-04-18
MXPA02005695A (es) 2002-09-18
AU778869B2 (en) 2004-12-23
TR200402293T2 (tr) 2004-10-21
IL149496A (en) 2009-12-24
EP1286668B1 (en) 2005-04-27
AU2005200797A1 (en) 2005-03-17
DK1286668T3 (da) 2005-08-15
TWI263496B (en) 2006-10-11
PT1286668E (pt) 2005-08-31
AU2672801A (en) 2001-06-18
NO20022680L (no) 2002-08-12
HUP0301122A3 (en) 2005-03-29
PL202201B1 (pl) 2009-06-30
AR026916A1 (es) 2003-03-05
CN1875966A (zh) 2006-12-13
NZ531489A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
SG152025A1 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
GB2295318B (en) Freeze-dried dosage form containing ondansetron
HUT76644A (en) Substituted piperidines, pharmaceutical compositions containing them and their use
IL116083A (en) Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
IS4407A (is) Notkun samsetningarafurðar sem inniheldur samkeppnishæf prógesterónmótlyf og gestagen til framleiðslu á læknislyfi til meðhöndlunar á legslímuvillu eða bandvefsvöðvahnútum í legi
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
RU2002105377A (ru) Ксенон-антагонист nmda
WO2007071394A3 (en) Combination of a 5-ht4 agonist with a cholinesterase inhibitor
MY129314A (en) Pharmaceutical composition comprising sumatriptan
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
TW200501948A (en) Composition for improving cognition and memory
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
MXPA02012574A (es) Uso novedoso de los antagonistas ii de angiotensina.
MY141659A (en) Biologically active 4h-benzo[1,4]oxazin-3-ones.
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
ECSP003820A (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
MY138979A (en) The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine